
|Videos|March 19, 2015
Sipuleucel-T: Evidence-based Use
Advertisement
Episodes in this series

Advertisement
Related to this article

The top 5 OncLive TV videos of the week cover insights in HER2+ breast cancer, NSCLC, ovarian cancer, prostate cancer, and sarcoma.

The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.

Phase 2 Co-PSMA data showed higher lesion detection with 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 in biochemical recurrence after prostatectomy.

Experts weigh genomic testing, treatment intensification, and radioligand sequencing in advanced prostate cancer care.

A dual antigen–targeted T-cell engager doublet produced durable PSA responses in late-line metastatic castration-resistant prostate cancer.

VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Neladalkib for Locally Advanced or Metastatic ALK+ NSCLC
2
Pertuzumab Biosimilar Gains FDA Approval for HER2+ Breast Cancer
3
FDA Removes Limitations of Use for Liso-Cel in Primary Central Nervous System Lymphoma
4
FDA Accepts sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis
5











